Breast Cancer
Conference Coverage
Lower CTC count IDs indolent MBC disease subset
A CTC count less than 5 per 7.5 mL of blood in MBC patients indicates an indolent disease subset, pooled data from two large cohorts show.
From the Journals
Breast cancer patients don’t get the financial counseling they want from their clinicians
About half of medical oncologists, and fewer surgeons and radiation oncologists, have someone in their practice to discuss the financial...
Conference Coverage
Trio of biosimilars have good showing
CHICAGO – Biosimilars for three widely used oncology drugs showed efficacy and safety similar to those of the reference products in lung cancer...
News
FDA expands indication for ribociclib for advanced breast cancer
Approval of the CDK 4/6 inhibitor was expanded to include the treatment of pre/perimenopausal women with HR-positive, HER2-negative, in...
From the Journals
ABP 980 similar to trastuzumab in HER2+ breast cancer in all but name
The LILAC trial comparing ABP 980 to trastuzumab missed its primary endpoint, but the biosimilar outperformed the reference drug in efficacy.
Conference Coverage
Trastuzumab biosimilar is equivalent on central review
CHICAGO – In a 20-country neoadjuvant trial, findings when tissue was centrally reviewed differed somewhat from those when tissue was reviewed...
From the Journals
Higher BMI tied to lower breast cancer risk in women before menopause
The effect was strongest in women aged 18-24 years, when it spanned breast cancer subtypes.
From the Editor
ASCO 2018: Less is more as ‘tailoring’ takes on new meaning
Original Report
The long-term effects of posttreatment exercise on pain in young women with breast cancer
From the Journals
Rural cancer patients report faster care than urban counterparts
In contrast to previous studies, urban patients reported longer delays in care, scoring “Getting Care Quickly” 2.27 points lower than rural...
Conference Coverage
Everolimus/exemestane improves PFS of ER+/HER2– breast cancer vs. everolimus alone
In this phase 2 randomized study, adding exemestane had better efficacy than did single-agent everolimus, but single-agent capecitabine appeared...